Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2410705 | Vaccine | 2006 | 7 Pages |
Abstract
Human Papillomavirus (HPV)-6 and -11 are the causative agents of ano-genital warts (GWs) and recurrent respiratory papillomatosis (RRP). They are low-risk HPV types that are uncommonly found in malignant lesions. GWs are an extremely prevalent sexually transmitted disease, whereas RRP is a rare disease that can be life threatening and requires multiple surgical procedures. GWs and RRP cause substantial healthcare costs. A quadrivalent HPV-6/11/16/18 vaccine (Merck/SPMSD) has shown essentially 100% protection against GWs in women in early studies. Cost-effectiveness analyses are needed to assess the benefits of the HPV-6/11 virus-like particle (VLP) components of the quadrivalent vaccine in population-based vaccination programmes.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Charles J.N. Lacey, Catherine M. Lowndes, Keerti V. Shah,